Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Deena Beasley (Reuters) - Resuming the use of Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine in the United States will require clear guidelines for the medical community on...
(Reuters) - Some countries are restricting use of the AstraZeneca (NASDAQ:AZN) COVID-19 vaccine to certain age groups, or suspending use, after European and British regulators...
By Sonali Paul MELBOURNE (Reuters) - Australia plans to accelerate the rollout of COVID-19 vaccines to people over 50 after advising under-50s not to get the AstraZeneca...
Following last week’s RBNZ monetary policy decision, this week, the central bank torch will be passed to the BoC and the ECB, with market participants eager to find out whether...
The global economic recovery is gaining momentum as the world’s two largest economies continue to deliver robust economic readings. China’s economy grew 18.3% in the...
The fact that neither the dollar nor US interest rates rose after the stronger than expected March CPI and real sector that prompted upward revisions to GDP forecasts may be saying...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 331.87 | 337.38 | 327.88 | -10.13 | -2.96% | 2.19M | NASDAQ | |||
| 22.12 | 22.23 | 21.83 | -0.34 | -1.54% | 6.33M | NYSE | |||
| 168.00 | 171.99 | 166.03 | +13.31 | +8.60% | 1.90M | NYSE | |||
| 9.35 | 9.94 | 9.18 | +0.53 | +6.01% | 25.86M | NASDAQ | |||
| 119.24 | 119.24 | 118.00 | +0.41 | +0.34% | 38.90K | NASDAQ | |||
| 0.93 | 0.00 | 0.00 | +0.08 | +9.45% | 30.23M | NASDAQ | |||
| 1.04 | 1.05 | 1.03 | -0.0200 | -1.89% | 982.05K | NYSE | |||
| 13.57 | 14.08 | 13.33 | +2.430 | +21.81% | 14.86M | NASDAQ | |||
| 5.79 | 5.80 | 5.72 | -0.03 | -0.52% | 801.81K | NYSE | |||
| 55.37 | 55.43 | 54.87 | +0.27 | +0.49% | 138.94K | NYSE | |||
| 10.79 | 10.79 | 10.79 | +0.09 | +0.84% | 7.17K | NYSE | |||
| 11.00 | 11.00 | 10.95 | +0.05 | +0.46% | 20.76K | NYSE | |||
| 29.78 | 29.78 | 29.78 | -0.17 | -0.57% | 22.34K | NYSE | |||
| 4.28 | 4.28 | 4.20 | +0.02 | +0.47% | 658.16K | NYSE | |||
| 79.54 | 79.54 | 79.36 | +0.39 | +0.49% | 23.91K | NASDAQ |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.